UT Austin Seed Fund Launched With First Investment to College of Pharmacy Research

A tall clock tower with trees enveloping it in the foreground.
December 1, 2022
The newly-created UT Seed Fund, which will provide funds to the most promising new startups built on university-owned intellectual property, will first invest in Jurata Thin Film, a startup based on the research discoveries of the College of Pharmacy's Maria Croyle, Ph.D., a professor in the Division of Molecular Pharmaceutics and Drug Delivery. Founded in 2019, Jurata has revolutionized the way vaccines and biologics are manufactured, distributed, stored and delivered across the world.

Croyle Wins Best Paper in 2022 Co-op Research Excellence Awards

A woman smiling.
November 4, 2022
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle, Ph.D. earned this year's Best Paper Award from the University Co-op Research Excellence Awards, presented by UT's Office of the Vice President for Research, Scholarship and Creative Endeavors and the University Co-operative Society.

Summer Programs of Innovation and Diversity

LEADER/PEPP Program participants and leaders sitting together at an outdoor table for lunch.
September 6, 2022
This summer, the office of Diversity, Equity, Accessibility, and Inclusion (DEAI), hosted two intensive summer research programs: Project Engage Pharmacy Program (PEPP) Camp and the Leadership Through Engagement For the Advancement of Diverse Educational Research (LEADER) Program.

Texas Pharmacy Rises to #8 Nationally for Total Research Funding

#8 Total Research Funding Rank for UT Pharmacy.
June 15, 2021
The University of Texas at Austin College of Pharmacy moved up in several research funding categories, as reported in the newly-released rankings from the American Association of Colleges of Pharmacy (AACP). The college rose to #8 nationally in total research funding during the 2019-2020 fiscal year, compared to #9 in 2018-2019.

Has a UT Professor Found a Way to Stop COVID-19 Vaccines From Spoiling?

A fruit roll treat floating in the clouds with a rainbow behind it and small viruses hovering around it.
February 24, 2021
Molecular Pharmaceutics and Drug Delivery Professor Maria A. Croyle, Ph.D. received extensive coverage in the March 2021 edition of Texas Monthly regarding her innovative peelable film drug delivery research. Among its many potential applications, Dr. Croyle’s technology could deliver COVID-19 vaccines through a small oral strip, without need for refrigeration or extensive storage and transportation infrastructure.

UT Pharmacy's Vital Vaccination Role

Five people in lab coats wearing masks.
January 15, 2021
Dean Sam Poloyac discusses the college's pivotal role in the university's effort to vaccinate everyone in the UT community.

Croyle Earns Funding for SARS-CoV-2 Research

A woman smiling.
January 13, 2021
Molecular Pharmaceutics and Drug Delivery professor Maria A. Croyle R.Ph., Ph.D. earned 2021’s David Lehr Research Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET). Dr. Croyle will receive research funding to investigate novel regulatory mechanisms of drug metabolism in the context of active infection with SARS-CoV-2 and after recovery.

A Message from Dr. Sam Poloyac on His First Day as Dean

A man smiling.
October 15, 2020
Samuel M. Poloyac, Pharm.D., Ph.D. addresses the community on his first day as dean of The University of Texas at Austin College of Pharmacy.

New Thin Film Technology to Revolutionize Storage and Distribution of Biologic Treatments and Vaccines

A hand touching a transparent sheet.
September 29, 2020
The newly-formed Jurata Thin Film will work to bring Dr. Maria Croyle's thin film technology to market, allowing biologics and vaccines to be packaged, shipped, and stored at room temperature for extended periods of time.

Inhaled Niclosamide a Potential Effective Antiviral to Treat COVID-19

An infrared image of nasal spray being administered.
September 29, 2020
Researchers in the lab of Dr. Hugh D.C. Smyth have released promising results of a new method to treat SARS-CoV-2, the coronavirus that causes COVID-19. The antiviral niclosamide, when incorporated with human lysozyme as a carrier molecule, shows potential as an effective COVID-19 treatment when delivered directly to the airways.